Cardiologists prescribing rivaroxaban more than warfarin
Cardiologists are increasingly bypassing the anticoagulant warfarin in favor of rivaroxaban, a more-expensive alternative with fewer side effects, according to the IMS NPA Weekly.
Cardiologists are increasingly bypassing the anticoagulant warfarin in favor of rivaroxaban, a more-expensive alternative with fewer side effects, according to the IMS NPA Weekly.
Janssen, the maker of rivaroxaban (Xarelto), recently reported that the drug captured 40% of the prescription market as of May 10, 2013, compared to the 35% share for warfarin. The FDA has approved rivaroxaban for the prevention of stroke in nonvalvular atrial fibrillation, several indications for deep vein thrombosis, and hip and knee surgery.
Rivaroxaban does not have to be monitored as frequently as warfarin, has few drug-drug interactions, and has practically no drug-food interactions. However, rivaroxaban is more costly, about $8 per pill, compared to warfarin, according to IMS NPA Weekly.
Also, with rivaroxaban there is no antidote to reverse its drug thinning effect, whereas warfarin does have specific reversal agents for bleeding.
Psychiatric Pharmacist Working to Optimize Treatment, Improve Patient Safety
December 13th 2024A conversation with Nina Vadiei, PharmD, BCPP, clinical associate professor in the Division of Pharmacotherapy at University of Texas at Austin College of Pharmacy and a clinical pharmacy specialist in psychiatry at the San Antonio State Hospital.
